NeoVirTech
Biotechnology Research • 
Toulouse, Occitanie, France • 1-10 Employees
Company overview
| Headquarters | 1 place Pierre Potier, Oncopole, entrée B, Toulouse, 31106, FR |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Imaging, Biotech, Virology, Custom Design, Anti-Viral Compounds, Fluorescence Microscopy, High Content Screening, Gene Therapy, Vaccine, Oncolytic Virus, Drug Screening, High Content Imaging |
| Founded | 2014 |
| Employees | 1-10 |
| Socials |
Key Contact at NeoVirTech
Franck Gallardo
Chief Executive Officer
NeoVirTech Email Formats
NeoVirTech uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@neovirtech.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@neovirtech.com | 66.7% |
{first initial}{last name} | jdoe@neovirtech.com | 33.3% |
About NeoVirTech
NeoVirTech (NVT) is one of the leading virus imaging and antiviral discovery company in Europe. The company has been highlighted in the Top10 drug discovery companies, Europe, 2019 by the PharmaTechOutlook Magazine. NVT has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells, from high resolution to high content imaging. At NeoVirTech, we believe everyone can have access to state-of-the-art virology techniques. We are focusing our activities on antiviral discovery, study of oncolytic and gene therapy products and quantification of disinfection procedures (physical, chemical, radiative) on a strong collection of pathogenous viruses impacting the human, animal and biodefence market. We work in classical BSL2 lab (Herpes, adenovirus, ...), BSL2+ level (influenza H1N1, RSV, rhinovirus) to BSL3 confinement (highly pathogenous influenza, SARS-CoV-2). With our ANCHOR technology, we can directly visualize virus infection and replication in living cells without fixation, extraction or reagents. Customers use our service to identify rapidly and efficiently new antiviral molecules, calibrate disinfection devices, investigate oncolytic virus behavior or understand the biology of gene therapy vectors. Our technologies relies on state off the art microscopy platform, providing our customers qualitative images for communication and marketing operations. If viruses is of your concern, contact us: contact@neovirtech.com More informations: www.neovirtech.com
NeoVirTech revenue & valuation
| Annual revenue | $513,330 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,700,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
NeoVirTech has 4 employees across 2 departments.
Departments
Number of employees
Funding Data
NeoVirTech has never raised funding before.
NeoVirTech Tech Stack
Discover the technologies and tools that power NeoVirTech's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
JavaScript libraries
Caching
JavaScript libraries
JavaScript libraries
Cookie compliance
JavaScript libraries
UI frameworks
Page builders
JavaScript libraries
Web servers
United Kingdom
United States
Australia
Germany
Frequently asked questions
4.8
40,000 users
